2 completed, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Oryzon Genomics S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Iadademstat, Paclitaxel - Small-cell Lung Cancer, Neuroendocrine Carcinoma | Phase 2 | Terminated | Fox Chase Cancer Center | 20 | 2022-12-21 | 2025-07-30 |
| Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population vafidemstat, Placebo - Borderline Personality Disorder | Phase 2 | Completed | Oryzon Genomics S.A. | 211 | 2021-03-26 | 2026-05-05 |
| Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease ORY-2001 Low dose, ORY-2001 High dose, Placebo - Mild to Moderate Alzheimer's Disease | Phase 2 | Completed | Oryzon Genomics S.A. | 24 | 2019-05-16 | 2021-03-05 |
Alzheimer Disease (1) · Borderline Personality Disorder (1) · Carcinoma, Neuroendocrine (1) · Small Cell Lung Carcinoma (1)
vafidemstat (2) · Paclitaxel (1) · iadademstat (1)
United States (3) · Bulgaria (1) · Germany (1) · Serbia (1) · Spain (1)
Michael Ropacki, MD (2) · Namrata Vijavergia (1)